

Reference:	FOI.19838.26
Subject:	Urothelial cancer
Date of Request:	4 March 2026

Requested:

1. Do you treat patients for urothelial cancer within your trust? (Yes/No)
 - If No, to which trust(s) do you typically refer patients for treatment?

2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:
 - Atezolizumab (Tecentriq)
 - Avelumab (Bavencio)
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Gemcitabine + Avelumab (Bavencio)
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin with Gemcitabine + Nivolumab (Opdivo)
 - Cisplatin with Gemcitabine + Avelumab (Bavencio)
 - Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)
 - Nivolumab (Opdivo)
 - Pembrolizumab (Keytruda)
 - Other active systemic anti-cancer therapy
 - Palliative care only
 - Erdafitinib
 - Cisplatin + Gemcitabine + Durvalumab (Imfinzi)
 - BCG therapy
 - Chemo-Radiation Therapy

3. In the Metastatic urothelial cancer setting only, how many patients in the past 3 months were treated with the following systemic anti-cancer therapies first line approaches?
 - Carboplatin single agent or in any other combination
 - Carboplatin with Gemcitabine
 - Carboplatin with Gemcitabine + Avelumab (Bavencio)
 - Carboplatin with Paclitaxel
 - Cisplatin single agent or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin with Gemcitabine + Avelumab (Bavencio)
 - Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)
 - Atezolizumab (Tecentriq) monotherapy
 - Palliative care only
 - Other

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all the information requested for questions 2 and 3, as it is estimated that the cost of answering your request would

exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with the data requested for Bacillus Calmette-Guérin (BCG) therapy and palliative care, the UHB would need to undertake a manual trawl of patient medical records, to identify those diagnosed with Urothelial cancer, as this is not recorded centrally.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable to individuals who have made a request under the FoIA, this can include assisting a requestor to further refine their request.

Unfortunately, the UHB is unable to provide advice on how you can refine your request further. This is due to the UHB still requiring a manual trawl of all Urothelial cancer patient records to be undertaken, to identify any information to fulfil these parts of your request.

Additionally, where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. Hywel Dda University Health Board (UHB) confirms that it does treat patients for Urothelial cancer.
2. The UHB provides within the table below, the number of patients that were treated for Urothelial cancer, at any stage, with the listed medications, during the period 1 December 2025 to 28 February 2026.

Medication	Number
Atezolizumab (Tecentriq)	*
Avelumab (Bavencio)	6
Carboplatin single agent or in any other combination	0
Carboplatin with Gemcitabine	*
Carboplatin with Gemcitabine + Avelumab (Bavencio)	0
Carboplatin with Paclitaxel	0
Cisplatin single agent or in any other combination	0
Cisplatin with Gemcitabine	0

Cisplatin with Gemcitabine + Nivolumab (Opdivo)	0
Cisplatin with Gemcitabine + Avelumab (Bavencio)	0
Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)	*
Nivolumab (Opdivo)	*
Pembrolizumab (Keytruda)	0
Other active systemic anti-cancer therapy	*
Palliative care only	Section 12 exemption applied
Erdafitinib	0
Cisplatin + Gemcitabine + Durvalumab (Imfinzi)	0
BCG therapy	Section 12 exemption applied
Chemo-Radiation Therapy	0

3. The UHB provides within the table below, the number of metastatic Urothelial cancer patients treated with the first line systemic anti-cancer therapies listed, 1 December 2025 to 28 February 2026.

Therapy	Number
Carboplatin single agent or in any other combination	0
Carboplatin with Gemcitabine	*
Carboplatin with Gemcitabine + Avelumab (Bavencio)	0
Carboplatin with Paclitaxel	0
Cisplatin single agent or in any other combination	0
Cisplatin with Gemcitabine	0
Cisplatin with Gemcitabine + Avelumab (Bavencio)	0
Pembrolizumab + Enfortumab Vedotin (Keytruda + Padcev)	*
Atezolizumab (Tecentriq) monotherapy	*
Palliative care only	Section 12 exemption applied
Other	6